Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > JP Morgan Conference

<< Previous

Bullboard Posts

Next >>

Comment by Marky1on Jan 10, 2021 3:13pm

175 Views

Post# 32263732

RE:JP Morgan Conference

When they say presenting, it is not a general presentation...They will be talking on a 1 to 1 to

companies, or instituions...meetings that have been arranged by Stern and our IR..

correct! If there is money to be made, it doesn't matter what time it is. Very True

<< Previous

Bullboard Posts

Next >>

The top 5 Canadian small-cap AI stocks